An Israeli study assessed the effectiveness of BNT162b2 COVID-19 vaccination (Pfizer) against the Omicron variant in children 5 to 11 years old using a large health care database and found the vaccine effectiveness (VE) to be 48 percent 7–21 days after dose 2 for symptomatic infection.
People with evidence of prior COVID infection by PCR, antigen, or serology test were excluded.
A U.S. study of a lesser scale found that VE in children declined from 60 percent to 28.9 percent from month 1 to month 2 after the second dose of Pfizer.
Cardiologist Sanjay Verma concluded that “therefore, if this Israeli study were to follow the children beyond 21 days, it is probable the VE would be lower than 48 percent.”…